Novartis Stalevo FIRST STEP Study Publication Press Release

Share

Patients with early Parkinson’s disease experienced better symptom control and improvements in daily activities with Stalevo® than carbidopa/levodopa, according to newly-published study.

Click for a printer friendly version

Back to top